Corrigendum to “Rates of susceptibility of carbapenems, ceftobiprole, and colistin against clinically important bacteria collected from intensive care units in 2007: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)” [J Microbiol Immunol Infect 49 (2016) 969–976] (S1684118215000213) (10.1016/j.jmii.2014.12.008));Rates of susceptibility of carbapenems, ceftobiprole, and colistin against clinically important bacteria collected from intensive care units in 2007: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)

Journal of Microbiology, Immunology and Infection

Volumn 49, Issue 6, 2016, Pages 969-976

  Jean, Shio Shin ^a   Lee, Wen Sen ^a   Yu, Kwok Woon ^b   Liao, Chun Hsing ^c   Hsu, Chin Wang ^a   Chang, Feng Yi ^d   Ko, Wen Chien ^e   Chen, Ray Jade ^a   Wu, Jiunn Jong ^f   Chen, Yen Hsu ^g   Chen, Yao Shen ^h   Liu, Jien Wei ⁱ   Lu, Min Chi ^j   Lam, Carlos ^a   Liu, Cheng Yi ^k   Hsueh, Po Ren ^l  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^d TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^g KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

ⁱ CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^j Chung Shan Medical and University   (Taiwan)

^k TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^l NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

more..

Author keywords

carbapenem; ceftobiprole; colistin; intensive care unit; nonsusceptibility

Indexed keywords

CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTOBIPROLE; CLAVULANIC ACID; COLISTIN; IMIPENEM; MEROPENEM; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CITROBACTER FREUNDII; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIC50; MIC90; MORGANELLA MORGANII; NONHUMAN; PENICILLIN RESISTANCE; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; TAIWAN; TEACHING HOSPITAL; DRUG EFFECTS; ENTEROBACTERIACEAE; EPIDEMIOLOGY; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; QUESTIONNAIRE;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CEPHALOSPORINS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; SURVEYS AND QUESTIONNAIRES; TAIWAN;

EID: 84922735991     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2017.01.001     Document Type: Erratum

References (33)

1. 1 Gould, I.M., Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. Int J Antimicrob Agents 31 (2008), 1–9.
2. 2 Wang, J.L., Wang, J.T., Sheng, W.H., Chen, Y.C., Chang, S.C., Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method. BMC Infect Dis, 10, 2010, 159.
3. 3 Rose, W.E., Leonard, S.N., Rossi, K.L., Kaatz, G.W., Rybak, M.J., Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 53 (2009), 805–807.
4. 4 Sakoulas, G., Moise-Broder, P.A., Schentag, J., Forrest, A., Moellering, R.C. Jr., Eliopoulos, G.M., Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42 (2004), 2398–2402.
5. 5 American Thoracic Society; Infectious Diseases Society of America, Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005), 388–416.
6. 6 Pillar, C.M., Aranza, M.K., Shah, D., Sahm, D.F., In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin. J Antimicrob Chemother 61 (2008), 595–602.
7. 7 Lodise, T.P. Jr., Pypstra, R., Kahn, J.B., Murthy, B.P., Kimko, H.C., Bush, K., et al. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob Agents Chemother 51 (2007), 2378–2387.
8. 8 Queenan, A.M., Shang, W., Bush, K., Flamm, R.K., Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole. Antimicrob Agents Chemother 54 (2010), 4092–4097.
9. 9 Davies, T.A., Flamm, R.K., Lynch, A.S., Activity of ceftobiprole against Streptococcus pneumoniae isolates exhibiting high-level resistance to ceftriaxone. Int J Antimicrob Agents 39 (2012), 534–538.
10. 10 Saravolatz, L.D., Pawlak, J., Johnson, L.B., Saravolatz, L.D. 2nd, Husain, N., In vitro activity of ceftobiprole against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA). Int J Antimicrob Agents 36 (2010), 478–480.
11. 11 Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing: twenty-fourth informational supplement M100–S24. 2014, CLSI, Wayne, PA, USA.
12. 12 Jean, S.S., Lee, W.S., Bai, K.J., Lam, C., Hsu, C.W., Yu, K.W., et al. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007. J Microbiol Immunol Infect 48 (2015), 85–91.
13. 13 Tzelepi, E., Giakkoupi, P., Sofianou, D., Loukova, V., Kemeroglou, A., Tsakris, A., Detection of extended-spectrum β-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes. J Clin Microbiol 38 (2000), 542–546.
14. 14 M'Zali, F.H., Chanawong, A., Kerr, K.G., Birkenhead, D., Hawkey, P.M., Detection of extended-spectrum β-lactamases in members of the family Enterobacteriaceae: comparison of the MAST DD test, the double disc and the Etest ESBL. J Antimicrob Chemother 45 (2000), 881–885.
15. 15 Ece, G., Samlioglu, P., Atalay, S., Kose, S., Evaluation of the in vitro colistin susceptibility of Pseudomonas aeruginosa and Acinetobacter baumannii strains at a tertiary care centre in Western Turkey. Infez Med 22 (2014), 36–40.
16. 16 Sader, H.S., Farrell, D.J., Flamm, R.K., Jones, R.N., Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009–2011). Diagn Microbiol Infect Dis 78 (2014), 443–448.
17. 17 Garbati, M.A., Bin Abdulhak, A., Baba, K., Sakkijha, H., Infection due to colistin-resistant Enterobacteriacae in critically-ill patients. J Infect Dev Ctries 7 (2013), 713–719.
18. 18 Zhanel, G.G., Lam, A., Schweizer, F., Thomson, K., Walkty, A., Rubinstein, E., et al. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Am J Clin Dermatol 9 (2008), 245–254.
19. 19 Rossolini, G.M., Dryden, M.S., Kozlov, R.S., Quintana, A., Flamm, R.K., Läuffer, J.M., et al., CLASS Study Group. Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study. J Antimicrob Chemother 66 (2011), 151–159.
20. 20 Fritsche, T.R., Sader, H.S., Jones, R.N., Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005–2006). Diagn Microbiol Infect Dis 61 (2008), 86–95.
21. 21 Sader, H.S., Fritsche, T.R., Jones, R.N., Antimicrobial activity of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA). Antimicrob Agents Chemother 52 (2008), 1153–1155.
22. 22 Lascols, C., Legrand, P., Mérens, A., Leclercq, R., Muller-Serieys, C., Drugeon, H.B., et al. In vitro antibacterial activity of ceftobiprole against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints. Int J Antimicrob Agents 37 (2011), 235–239.
23. 23 Jean, S.S., Hsueh, P.R., Lee, W.S., Yu, K.W., Liao, C.H., Chang, F.Y., et al. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: Results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009. Int J Antimicrob Agents 41 (2013), 457–462.
24. 24 Lee, C.M., Liao, C.H., Lee, W.S., Liu, Y.C., Mu, J.J., Lee, M.C., et al. Outbreak of Klebsiella pneumoniae carbapenemase-2-producing K. pneumoniae sequence type 11 in Taiwan in 2011. Antimicrob Agents Chemother 56 (2012), 5016–5022.
25. 25 Chiu, S.K., Wu, T.L., Chuang, Y.C., Lin, J.C., Fung, C.P., Lu, P.L., et al. National surveillance study on carbapenem non-susceptible Klebsiella pneumoniae in Taiwan: the emergence and rapid dissemination of KPC-2 carbapenemase. PLoS One, 8, 2013, e69428.
26. 26 Leavitt, A., Chmelnitsky, I., Colodner, R., Ofek, I., Carmeli, Y., Navon-Venezia, S., Ertapenem resistance among extended-spectrum-β-lactamase-producing Klebsiella pneumoniae isolates. J Clin Microbiol 47 (2009), 969–974.
27. 27 Woodford, N., Dallow, J.W., Hill, R.L., Palepou, M.F., Pike, R., Ward, M.E., et al. Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory. Int J Antimicrob Agents 29 (2007), 456–459.
28. 28 Martínez-Martínez, L., Pascual, A., Hernández-Allés, S., Alvarez-Díaz, D., Suárez, A.I., Tran, J., et al. Roles of β-lactamases and porins in activities of carbapenems and cephalosporins against. Klebsiella pneumoniae. Antimicrob Agents Chemother 43 (1999), 1669–1673.
29. 29 Jean, S.S., Hsueh, P.R., Lee, W.S., Chang, H.T., Chou, M.Y., Chen, I.S., et al. Nationwide surveillance of antimicrobial resistance among Enterobacteriaceae in intensive care units in Taiwan. Eur J Clin Microbiol Infect Dis 28 (2009), 215–220.
30. 30 Zhang, H., Yang, Q., Xiao, M., Chen, M., Badal, R.E., Xu, Y., Antimicrobial susceptibility of Gram-negative bacteria causing intra-abdominal infections in China: SMART China 2011. Chin Med J 127 (2014), 2429–2433.
31. 31 Mehtar, S., Tsakris, A., Pitt, T.L., Imipenem resistance in Proteus mirabilis. J Antimicrob Chemother 28 (1991), 612–615.
32. 32 Tsai, H.Y., Chen, Y.H., Tang, H.J., Huang, C.C., Liao, C.H., Chu, F.Y., et al. Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum β-lactamase-producing Proteus mirabilis. Diagn Microbiol Infect Dis 80 (2014), 222–226.
33. 33 Neuwirth, C., Siébor, E., Duez, J.M., Péchinot, A., Kazmierczak, A., Imipenem resistance in clinical isolates of Proteus mirabilis associated with alterations in penicillin-binding proteins. J Antimicrob Chemother 36 (1995), 335–342.